Induction chemotherapy by superselective intra-arterial high-dose carboplatin infusion for head and neck cancer

Marco Benazzo, G. Caracciolo, F. Zappoli, G. Bernardo, E. Mira

Research output: Contribution to journalArticle

Abstract

To evaluate the feasibility, maximum dose of drug tolerated, technical problems, systemic and local toxicity, response rate, overall and disease-free survival, we studied superselective intra-arterial infusion of high-dose carboplatin as part of a multimodality treatment for head and neck cancer. Forty patients with untreated stage II-IV head and neck squamous cell carcinomas received induction chemotherapy with high-dose carboplatin (three cycles at 2-week intervals using 300-350 mg/m2 per cycle), delivered via superselective transfemoral angiography followed by radiotherapy or surgery plus radiotherapy. No technical complications occurred during or after the infusion. Systemic toxicity was minimal, and local toxicity was moderate. At the end of chemotherapy the overall complete and partial response rate was 90% (36/40) at the primary site and 64% (16/25) at the neck nodes. The median follow-up was 24.4 months (range 3-52). To date 21 patients are alive without disease, 2 are alive with disease, 13 have died of disease, and 4 have developed a metachronous lung tumor. There was a good correlation between the response to chemotherapy and disease-free survival. No statistically significant benefit in survival was observed with respect to other series of head and neck tumors treated with different protocols. However, discriminating between responding and nonresponding patients, this procedure can have a prognostic significance in planning integrated treatments for these types of tumors.

Original languageEnglish
Pages (from-to)279-282
Number of pages4
JournalEuropean Archives of Oto-Rhino-Laryngology
Volume257
Issue number5
Publication statusPublished - 2000

Fingerprint

Induction Chemotherapy
Carboplatin
Head and Neck Neoplasms
Disease-Free Survival
Neck
Radiotherapy
Drug Therapy
Intra Arterial Infusions
Neoplasms
Maximum Tolerated Dose
Angiography
Head
Lung
Survival
Therapeutics
Pharmaceutical Preparations

Keywords

  • Carboplatin
  • Head and neck cancer
  • Intra-arterial chemotherapy

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Induction chemotherapy by superselective intra-arterial high-dose carboplatin infusion for head and neck cancer. / Benazzo, Marco; Caracciolo, G.; Zappoli, F.; Bernardo, G.; Mira, E.

In: European Archives of Oto-Rhino-Laryngology, Vol. 257, No. 5, 2000, p. 279-282.

Research output: Contribution to journalArticle

@article{71ce5e79f73940578f21d1b3eda9ba40,
title = "Induction chemotherapy by superselective intra-arterial high-dose carboplatin infusion for head and neck cancer",
abstract = "To evaluate the feasibility, maximum dose of drug tolerated, technical problems, systemic and local toxicity, response rate, overall and disease-free survival, we studied superselective intra-arterial infusion of high-dose carboplatin as part of a multimodality treatment for head and neck cancer. Forty patients with untreated stage II-IV head and neck squamous cell carcinomas received induction chemotherapy with high-dose carboplatin (three cycles at 2-week intervals using 300-350 mg/m2 per cycle), delivered via superselective transfemoral angiography followed by radiotherapy or surgery plus radiotherapy. No technical complications occurred during or after the infusion. Systemic toxicity was minimal, and local toxicity was moderate. At the end of chemotherapy the overall complete and partial response rate was 90{\%} (36/40) at the primary site and 64{\%} (16/25) at the neck nodes. The median follow-up was 24.4 months (range 3-52). To date 21 patients are alive without disease, 2 are alive with disease, 13 have died of disease, and 4 have developed a metachronous lung tumor. There was a good correlation between the response to chemotherapy and disease-free survival. No statistically significant benefit in survival was observed with respect to other series of head and neck tumors treated with different protocols. However, discriminating between responding and nonresponding patients, this procedure can have a prognostic significance in planning integrated treatments for these types of tumors.",
keywords = "Carboplatin, Head and neck cancer, Intra-arterial chemotherapy",
author = "Marco Benazzo and G. Caracciolo and F. Zappoli and G. Bernardo and E. Mira",
year = "2000",
language = "English",
volume = "257",
pages = "279--282",
journal = "European Archives of Oto-Rhino-Laryngology",
issn = "0937-4477",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Induction chemotherapy by superselective intra-arterial high-dose carboplatin infusion for head and neck cancer

AU - Benazzo, Marco

AU - Caracciolo, G.

AU - Zappoli, F.

AU - Bernardo, G.

AU - Mira, E.

PY - 2000

Y1 - 2000

N2 - To evaluate the feasibility, maximum dose of drug tolerated, technical problems, systemic and local toxicity, response rate, overall and disease-free survival, we studied superselective intra-arterial infusion of high-dose carboplatin as part of a multimodality treatment for head and neck cancer. Forty patients with untreated stage II-IV head and neck squamous cell carcinomas received induction chemotherapy with high-dose carboplatin (three cycles at 2-week intervals using 300-350 mg/m2 per cycle), delivered via superselective transfemoral angiography followed by radiotherapy or surgery plus radiotherapy. No technical complications occurred during or after the infusion. Systemic toxicity was minimal, and local toxicity was moderate. At the end of chemotherapy the overall complete and partial response rate was 90% (36/40) at the primary site and 64% (16/25) at the neck nodes. The median follow-up was 24.4 months (range 3-52). To date 21 patients are alive without disease, 2 are alive with disease, 13 have died of disease, and 4 have developed a metachronous lung tumor. There was a good correlation between the response to chemotherapy and disease-free survival. No statistically significant benefit in survival was observed with respect to other series of head and neck tumors treated with different protocols. However, discriminating between responding and nonresponding patients, this procedure can have a prognostic significance in planning integrated treatments for these types of tumors.

AB - To evaluate the feasibility, maximum dose of drug tolerated, technical problems, systemic and local toxicity, response rate, overall and disease-free survival, we studied superselective intra-arterial infusion of high-dose carboplatin as part of a multimodality treatment for head and neck cancer. Forty patients with untreated stage II-IV head and neck squamous cell carcinomas received induction chemotherapy with high-dose carboplatin (three cycles at 2-week intervals using 300-350 mg/m2 per cycle), delivered via superselective transfemoral angiography followed by radiotherapy or surgery plus radiotherapy. No technical complications occurred during or after the infusion. Systemic toxicity was minimal, and local toxicity was moderate. At the end of chemotherapy the overall complete and partial response rate was 90% (36/40) at the primary site and 64% (16/25) at the neck nodes. The median follow-up was 24.4 months (range 3-52). To date 21 patients are alive without disease, 2 are alive with disease, 13 have died of disease, and 4 have developed a metachronous lung tumor. There was a good correlation between the response to chemotherapy and disease-free survival. No statistically significant benefit in survival was observed with respect to other series of head and neck tumors treated with different protocols. However, discriminating between responding and nonresponding patients, this procedure can have a prognostic significance in planning integrated treatments for these types of tumors.

KW - Carboplatin

KW - Head and neck cancer

KW - Intra-arterial chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0034043478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034043478&partnerID=8YFLogxK

M3 - Article

C2 - 10923944

AN - SCOPUS:0034043478

VL - 257

SP - 279

EP - 282

JO - European Archives of Oto-Rhino-Laryngology

JF - European Archives of Oto-Rhino-Laryngology

SN - 0937-4477

IS - 5

ER -